Cardio3 Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.11.14	Cardio3 BioSciences Announces the Nomination of Three Co-Principal Investigators for Its CHART-2 Phase III Clinical Trial of C-Cure® for the Treatment of Heart Failure (Businesswire)
18.11.14	Cardio3 BioSciences Announces Q3 2014 Business Update (Businesswire)
05.11.14	Cardio3 Biosciences Acquires CorQuest Medical Inc. (Businesswire)
23.10.14	Cardio3 BioSciences Appoints Dr. Warren Sherman as Chief Medical Officer (Businesswire)
13.10.14	Cardio3 BioSciences Receives Authorization to Enroll Patients in Switzerland in Its Phase III Clinical Trial CHART-1 (Businesswire)
08.10.14	Cardio3 BioSciences Awarded Preferred Access Rights to All Mayo Clinic Center for Regenerative Medicine Portfolio (Businesswire)
02.10.14	Cardio3 BioSciences to Present at the Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa 7-9 October 2014, La Jolla, San Diego, CA (Businesswire)
01.10.14	Cardio3 BioSciences Announces New Business Development Strategy to Broaden Its Product Pipeline (Businesswire)
15.09.14	Cardio3 BioSciences Receives Approval for the Continuation of Its CHART-1 Phase III Clinical Trial from the DSMB (Businesswire)
09.07.14	Cardio3 BioSciences: Amendment to the Press Release Distributed on 9 July at 12.00 CET (Businesswire)
07.07.14	Cardio3 BioSciences to Enroll the 120th Patient for Its Chart-1 Study (Businesswire)
01.07.14	Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share (Businesswire)
16.06.14	Cardio3 BioSciences Announces a Capital Increase of €25 Million at €44 per share (Businesswire)
16.06.14	Cardio3 BioSciences Teams up with Medisun International to Create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture Aimed at Conducting Pivotal Clinical Programs in Greater China (Businesswire)
10.06.14	Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III Clinical Trial CHART-1 (Businesswire)
05.06.14	Cardio3 BioSciences Nominated for the European Mediscience Awards 2014 (Businesswire)
02.06.14	Cardio3 BioSciences Appoints Dr. Georges Rawadi as VP Business Development (Businesswire)
20.05.14	Cardio3 BioSciences Announces Q1 2014 Business Update and Confirms Previous Operational and Financial Guidance (Businesswire)
19.05.14	Cardio3 BioSciences Signs First Sales Contract for C-Cathez® (Businesswire)
06.05.14	EMA Grants Certification of Quality Data for C-Cure® to Cardio3 BioSciences (Businesswire)
10.04.14	Cardio3 BioSciences Receives Authorization to Enroll Patients in Ireland in its Phase III Clinical Trial CHART-1 (Businesswire)
07.04.14	Cardio3 BioSciences’ Advanced Regenerative Technology Featured in European Heart Journal (Businesswire)
26.03.14	Cardio3 BioSciences’ Cell Therapy Approach for Cardiac Repair Recognized in Nature Reviews Cardiology (Businesswire)
18.03.14	Cardio3 BioSciences Reports 2013 Financial Results and Business Update (Businesswire)
24.02.14	Cardio3 BioSciences Strengthens IP Portfolio with New US Patent (Businesswire)
07.02.14	Cardio3 BioSciences Publishes Its First Letter to Shareholders (Businesswire)
03.02.14	Cardio3 BioSciences SA : Information on the Total Number of Voting Rights and Shares (Businesswire)
20.01.14	Cardio3 BioSciences SA: Transparency Notification SRIW SA / SA SOFIPOLE (Businesswire)
09.01.14	Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial (Businesswire)
30.12.13	Cardio3 Biosciences Announces Participation at the 32Nd Annual JP Morgan Healthcare Conference in San Francisco (Businesswire)
16.12.13	Cardio3 BioSciences Raises € 4.0 Million in Non-Dilutive Funding from the Walloon Region (Businesswire)
11.12.13	Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions (Businesswire)
03.12.13	Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program (Businesswire)
25.11.13	Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant (Businesswire)
21.11.13	Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia (Businesswire)
12.11.13	Cardio3 BioSciences Announces Q3 2013 Business Update and Authorization to Enroll Patients in Poland in Its CHART-1 Phase III Clinical Trial (Businesswire)
23.10.13	Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1 (Businesswire)
17.10.13	Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Walloon Brabant (Businesswire)
11.10.13	Cardio3 BioSciences to Participate at the KBC Securities Benelux Biotech Healthcare Conference in New York on November 13 & 14 (Businesswire)
07.10.13	Cardio3 BioSciences strengthens management team by appointing Dr. Gaëtane Metz as Chief Operating Officer (Businesswire)
30.09.13	Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure in Spain (Businesswire)
28.08.13	Cardio3 BioSciences Announces Half Year Financial Results and Business Update (Businesswire)
25.07.13	Cardio3 BioSciences Obtains the Qualification of "Innovative Company” Resulting in Tax Incentives for Specific French Investors (Businesswire)
18.07.13	Cardio3 BioSciences SA: Information on The Total Number of Voting Rights and Shares (Businesswire)
15.07.13	Cardio3 BioSciences: Exercise of Over-allotment Option (Businesswire)
12.07.13	Cardio3 BioSciences : Information on the total number of voting rights and shares (Article 15 of the Law of 2 August 2007) (Businesswire)
04.07.13	Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Cardio3 Biosciences SA Reg Shs

Aktien Top/Flop

Meistgelesene Nachrichten